Seoul, Korea and Heidelberg, Germany, July, 17, 2024 – SK Biopharmaceuticals, a global biotech company, announced today that it has entered into a license agreement with Full-Life Technologies (“Full-Life”), a fully integrated global radiotherapeutics company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life’s “FL-091” radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers.

2024年7月17日，德国海德堡和韩国首尔——辐联科技有限公司（以下简称“辐联科技”），一家全面整合的国际化放射性药物治疗公司，今日宣布其与全球生物科技公司SK Biopharmaceuticals签署了一项对外授权许可协议。根据该协议，辐联科技授予SK Biopharmaceuticals对于FL-091放射性药物在全球范围内进行临床研究、开发、生产和商业化的独家权利，针对靶向神经降压素受体1型（NTSR1）阳性的癌症。

This licensing deal worth $571.5 million, which includes an upfront payment, and development and commercial milestones, separate from royalties, is in line with SK Biopharmaceuticals’ vision to become a global “Big Biotech” with R&D and commercialization capabilities extending beyond the central nervous system treatment area into oncology via emerging modality platforms such as radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD).

该项交易总额为5.715亿美元，包含首付款、研发及商业里程碑付款，另有特许权使用费未计算在内。这符合SK Biopharmaceuticals的愿景，即成为一个全球性的“大型生物技术公司”，其研发和商业化能力不仅限于中枢神经系统治疗领域，还通过新兴的治疗方式平台扩展到肿瘤学领域，如放射性药物治疗（RPT）和靶向蛋白降解（TPD）。

Under the terms of the agreement, SK Biopharmaceuticals will in-license the NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091 – as well as its back-up compounds – aimed at developing and commercializing it as an innovative anti-cancer drug.

根据协议条款，SK Biopharmaceuticals将授权引进靶向NTSR1的放射性药物偶联物（RDC）项目FL-091及其备选化合物，并将其开发成一款创新型抗肿瘤药物。

FL-091 is a small-molecule radioligand vector designed to deliver targeted radiation therapy to cancer cells by binding specifically to NTSR1, a receptor protein, which is selectively overexpressed in various types of solid tumors, including colorectal cancer, prostate cancer, and pancreatic cancer.

FL-091是一种小分子放射性配体载体，旨在通过特异性结合NTSR1，将放射性治疗药物精准递送至癌细胞。NTSR1是一种受体蛋白，在包括结直肠癌和胰腺癌在内的多种实体瘤中选择性高表达。

SK Biopharmaceuticals also has a right of first negotiation to license other pre-selected RDC programs of Full-Life.

SK Biopharmaceuticals还对辐联科技其他预选的RDC项目拥有优先谈判权。

The licensing serves as a pivotal catalyst for SK Biopharmaceuticals’ inorganic momentum and strategic advancement to be a leading global player in the medium-term.

该许可协议是SK Biopharmaceuticals无机增长势头和战略推进的关键催化剂，助力其在中期内成为全球领先的参与者。

Lanny Sun, Chief Executive Officer of Full-Life, said, “This agreement with SK Biopharmaceuticals highlights the potential of FL-091 in advancing cancer treatment and demonstrates SK Biopharmaceuticals' unwavering commitment to building an oncology business around medical innovation. We look forward to future collaborations with SK Biopharmaceuticals, and to leveraging its expertise and resources to advance radiopharmaceutical therapy. The agreement is aligned with our strategic vision of fostering global partnerships and making a meaningful impact on patients worldwide.”

辐联科技首席执行官孙沛淇先生表示：“与SK Biopharmaceuticals达成的此次合作突显了FL-091在推进癌症治疗方面的潜力，也充分体现了SK Biopharmaceuticals致力于以创新为核心发展肿瘤业务的坚定承诺。我们期待着未来与SK Biopharmaceuticals开展更多的合作，借助其专业知识和资源推进放射药物治疗的发展。该项协议也符合我们促进全球合作伙伴关系的战略愿景，并致力于对全球患者产生积极影响。”

Donghoon Lee, Chief Executive Officer and President of SK Biopharmaceuticals, said, “The licensing agreement with Full-Life not only brings the two companies closer together for future collaborations in the fastest rising biotech sector, but also most importantly, pushes SK Biopharmaceuticals forward to become a ‘Big Biotech.’ Since the introduction of the company’s strategy roadmap to venture into radiopharmaceuticals last year, we have been on track toward our envisioned goal. We expect to further unveil and implement business plans for RPT this year, and actively pursue clinical development and commercialization in the near future to provide treatment options and create new value worldwide.”

SK Biopharmaceuticals首席执行官兼总裁Donghoon Lee先生表示：“与辐联科技的合作不仅使两家公司在快速崛起的生物技术领域建立了更加紧密的未来合作关系，更重要的是推动SK Biopharmaceuticals向成为“大型生物技术公司”的目标阔步迈进。自去年公司宣布进军放射性药物领域的战略路线以来，我们一直在朝着既定的目标稳步前进。我们期待在今年进一步公布并实施RPT（放射性治疗）的业务计划，并在不久的将来积极推动临床开发和商业化，在全球范围内提供更多的治疗选择并创造全新价值。”

About FL-091

关于FL-091

FL-091 is a novel small-molecule radioligand vector targeting NTSR1 positive solid tumors. Overexpression of NTSR1 has been associated with disease progression of multiple types of cancers, including colorectal, breast, pancreatic, and head and neck cancers. FL-091 radioligands have demonstrated favorable biodistribution profiles and enhanced binding affinity to NTSR1, as well as encouraging anti-tumor activities in preclinical studies. The development of the alpha-emitter therapy candidate 225Ac-FL-091 targeting NTSR1-positive tumors is currently in progress.

FL-091是一款靶向NTSR1阳性实体瘤的创新型小分子放射性配体载体。NTSR1的过度表达与多种癌症的疾病进展有关，包括结直肠癌、乳腺癌、胰腺癌以及头颈癌，FL-091放射性配体已展现出良好的生物分布特性和显著增强的NTSR1结合亲和力，以及优异的抗肿瘤活性。目前，靶向NTSR1阳性癌症的α疗法候选药物225Ac-FL-091的正处于开发阶段。

About SK Biopharmaceuticals

关于SK Biopharmaceuticals

SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts. SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI®) in the U.S. More than 100,000 patients have been treated globally with cenobamate, developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc., since its launch in the U.S. in 2020. Cenobamate has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa. The company also has a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals’ website at www.SKBP.com/eng, and SK Life Science’s website at www.SKLifeScienceInc.com.

SK Biopharmaceuticals专注于中枢神经系统（CNS）和抗肿瘤疗法的研究、开发和商业化。2017年，SK Biopharmaceuticals为了向肿瘤学领域拓展，特别成立了研究中心，并致力于通过研发工作在该领域取得突破。SK Biopharmaceuticals是第一家也是唯一一家在美国独立开发和商业化抗癫痫药物Cenobamate（商品名：XCOPRI®）的韩国公司。自2020年在美国推出以来，SK Biopharmaceuticals及其美国子公司SK Life Science, Inc.已向全球超过10万名患者提供了Cenobamate。此款药物已成功进入北美、欧洲、亚洲、中南美洲、中东和北非这五大地区。SK Biopharmaceuticals还在CNS和肿瘤疾病领域拥有八个在研化合物。此外，公司还专注于肿瘤新疗法的发现。

About Full-Life Technologies

关于辐联科技

Full-Life Technologies ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.

辐联科技有限公司（“辐联科技”）是一家全面整合的国际化放射性药物治疗公司，在比利时、德国和中国均设有办事处。辐联科技以全球患者为中心，致力于构建集放射性药物研发、生产和商业化为一体的全产业链核药公司，并通过领先的创新型研究解决现今放射性药物面临的根本性挑战，推动未来疗法发展。辐联科技团队由一支运作高效的企业家团队和经验丰富的科学家组成，他们在生命科学、放射性同位素研究和临床开发方面拥有丰富的成功经验。